(Q36872043)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614829%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

review article

1 reference

title

Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614829%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614829%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Stephen Y W Shiu

series ordinal

1

1 reference

16 August 2017

publication date

1 August 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614829%20AND%20SRC:MED&resulttype=core&format=json

Journal of Pineal Research

1 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614829%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614829%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614829%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

1-9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614829%20AND%20SRC:MED&resulttype=core&format=json

The melatonin rhythm: both a clock and a calendar

1 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Characterizing a mammalian circannual pacemaker

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

The validity of melatonin as an oncostatic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Melatonin in cancer management: progress and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Light pollution, melatonin suppression and cancer growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Role of pineal gland in aetiology and treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Melatonin and mammary cancer: a short review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Reduced cancer incidence among the blind

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Human melatonin production decreases with age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Aging and the circadian rhythm of melatonin: a cross-sectional study of Chinese subjects 30-110 yr of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Potential involvement of mt1 receptor and attenuated sex steroid-induced calcium influx in the direct anti-proliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Hormonal interactions in human prostate tumor LNCaP cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Melatonin receptors step into the light: cloning and classification of subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

MT-1 melatonin receptor expression increases the antiproliferative effect of melatonin on S-91 murine melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Melatonin inhibits fatty acid transport in inguinal fat pads of hepatoma 7288CTC-bearing and normal Buffalo rats via receptor-mediated signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Melatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potenti

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Differential expression of high-affinity melatonin receptors (MT1) in normal and malignant human breast tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Involvement of the mt1 melatonin receptor in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Melatonin-estrogen interactions in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Antiproliferative activity of melatonin by transcriptional inhibition of cyclin D1 expression: a molecular basis for melatonin-induced oncostatic effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Nuclear exclusion of the androgen receptor by melatonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Evaluation of signal transduction pathways mediating the nuclear exclusion of the androgen receptor by melatonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Role of protein kinase Calpha in melatonin signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Can prostate cancer be prevented?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Genetic and environmental factors in prostate cancer genesis: identifying high-risk cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Clinical evolution of prostatic intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Contribution of the androgen receptor to prostate cancer predisposition and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

5α-Reductase Type 1 Immunostaining is Enhanced in Some Prostate Cancers Compared With Benign Prostatic Hyperplasia Epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Pten is essential for embryonic development and tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Pten dose dictates cancer progression in the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Cancer: crime and punishment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

EAU guidelines on prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Curative treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Active surveillance for prostate cancer: for whom?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Androgen deprivation therapy for prostate cancer: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Mechanisms of androgen-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Melatonin: reducing the toxicity and increasing the efficacy of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Is there a role for melatonin in supportive care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Melatonin as a radioprotective agent: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Mouse modeling in oncologic preclinical and translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Melatonin: from basic research to cancer treatment clinics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2007.00451.X

10.1111/J.1600-079X.2007.00451.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17614829%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference